title: The effect of growth hormone treatment on biochemical indices in hypophosphatemic rickets.
abstract: BACKGROUND
  Growth hormone (GH) in combination with conventional therapy in hypophosphatemic rickets (HR) has been shown to promote renal phosphate (P) conservation and to result in a better metabolic control. This study aimed at investigating the acute biochemical effects of GH in 7 patients (5 female, 2 male) with HR aged between 2.16 and 16 years.
  
  
  METHODS
  Each patient received the following in a sequential design: oral P plus 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] therapy to determine the optimum doses for baseline requirement followed by GH-only therapy and GH +1,25-(OH)(2)D(3) therapy and GH + P +1,25-(OH)(2)D(3) therapy each for 2 weeks with 1 washout week off treatment in between. GH was given at a dose of 0.03 mg/kg/day s.c. on a daily basis. The dose of oral P used ranged between 500 and 2,000 mg/day, and the dose of 1,25-(OH)(2)D(3) ranged between 0.25 and 0.5 microg/day and was kept constant for each child throughout the study.
  
  
  RESULTS
  Laboratory investigations repeated at the end of each treatment, and the first washout period showed that the serum P level was highest (2.9 ng/ml) during the GH + P + 1,25-(OH)(2)D(3) period with higher serum 1,25-(OH)(2)D(3) levels: 50.9 +/- (SD) 23.4 ng/l. Parathyroid hormone and alkaline phosphatase levels did not show a significant difference between the periods. The tubular P reabsorption rate showed an insignificant increase during GH therapy periods.
  
  
  CONCLUSIONS
  Considering the fixed dose of P and calcitriol, it may be concluded that GH added to conventional treatment in HR resulted in a slight improvement in the biochemical parameters without any side effects at the short term.
authors.affiliation: Department of Pediatrics, Istanbul Faculty of Medicine, TR-34390 Capa-Istanbul, Turkey. darendeliler@superonline.com
authors.forename: F
authors.initials: F
authors.lastname: Darendeliler
authors.forename: F
authors.initials: F
authors.lastname: Baş
authors.forename: N
authors.initials: N
authors.lastname: Karaaslan
authors.forename: N
authors.initials: N
authors.lastname: Hekim
authors.forename: R
authors.initials: R
authors.lastname: Bundak
authors.forename: N
authors.initials: N
authors.lastname: Saka
authors.forename: H
authors.initials: H
authors.lastname: Günöz
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D017674:Hypophosphatemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D012279:Rickets / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D019382:Human Growth Hormone